Poseida Therapeutics, Inc. Contracts & Agreements

Poseida Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 14, 2024)

Offer Letter, by and between the Registrant and Syed Rizvi, M.D., dated March 15, 2024 (Filed With SEC on May 14, 2024)

Second Amendment to the Collaboration and License Agreement, dated February 7, 2024, by and among the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc (Filed With SEC on May 14, 2024)

First Amendment to the Collaboration and License Agreement, dated November 7, 2023, by and among the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc (Filed With SEC on March 7, 2024)

Executive Employment Agreement, by and between the Company and Kristin Yarema, Ph.D., dated January 1, 2024 (Filed With SEC on January 4, 2024)

Amended and Restated Participation Agreement, by and between the Company and Kristin Yarema, Ph.D., dated January 1, 2024 (Filed With SEC on January 4, 2024)

Second Amended and Restated Executive Employment Agreement, by and between the Company and Mark Gergen, dated January 1, 2024 (Filed With SEC on January 4, 2024)

Poseida Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on November 9, 2023)

Consent and First Amendment to Loan and Security Agreement, by and among the Registrant and Oxford Finance LLC, dated July 19, 2023 (Filed With SEC on August 8, 2023)

Securities Purchase Agreement, by and between the Company and Astellas, dated August 4, 2023 (Filed With SEC on August 7, 2023)

Registration Rights Agreement, by and between the Company and Astellas, dated August 4, 2023 (Filed With SEC on August 7, 2023)

Strategic Rights Letter Agreement, by and between the Company and Astellas, dated August 4, 2023 (Filed With SEC on August 7, 2023)

Poseida Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 11, 2022)

Purchase Agreement, dated August 3, 2022, by and among Poseida Therapeutics, Inc., Piper Sandler & Co. and William Blair & Company, L.L.C, as representatives of the several... (Filed With SEC on August 4, 2022)

Collaboration and License Agreement, by and between the Registrant and Takeda Pharmaceuticals USA, Inc., effective October 11, 2021 (Filed With SEC on March 10, 2022)

Loan and Security Agreement, by and among the Registrant, Vindico NanoBioTechnology, LLC and Oxford Finance LLC, dated February 22, 2022 (Filed With SEC on March 10, 2022)

Amended and Restated Executive Employment Agreement, by and between the Company and Mark Gergen, dated February 1, 2022 (Filed With SEC on February 1, 2022)

Amended and Restated Participation Agreement, by and between the Company and Mark Gergen, dated February 1, 2022 (Filed With SEC on February 1, 2022)

Amended and Restated Executive Employment Agreement, by and between the Company and Eric Ostertag, M.D., Ph.D., dated February 1, 2022 (Filed With SEC on February 1, 2022)

Amended and Restated Participation Agreement, by and between the Company and Eric Ostertag, M.D., Ph.D., dated February 1, 2022 (Filed With SEC on February 1, 2022)

Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the Poseida Therapeutics, Inc. 2020 Equity Incentive Plan (Filed With SEC on November 9, 2021)

Fifth Amendment to Loan and Security Agreement, by and among the Registrant, Vindico NanoBioTechnology, LLC and Oxford Finance LLC, dated June 24, 2021 (Filed With SEC on August 12, 2021)

Amended and Restated License Agreement, by and between the Registrant and Helmholtz-Zentrum MnchenDeutsches Forschungszentrum fr Gesundheit und Umwelt GmbH, executed as of March... (Filed With SEC on May 11, 2021)

Description of Common Stock (Filed With SEC on March 11, 2021)

Form of Underwriting Agreement (Filed With SEC on July 6, 2020)

Amended and Restated Investors Rights Agreement, by and among the Registrant and certain of its stockholders, dated June 24, 2020 (Filed With SEC on July 6, 2020)

Poseida Therapeutics, Inc. 2015 Equity Incentive Plan, as amended, and Forms of Option Grant Notice, Option Agreement and Notice of Exercise thereunder (Filed With SEC on July 6, 2020)

Poseida Therapeutics, Inc. 2020 Equity Incentive Plan and Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder (Filed With SEC on July 6, 2020)

Poseida Therapeutics, Inc. 2020 Employee Stock Purchase Plan (Filed With SEC on July 6, 2020)

Poseida Therapeutics, Inc. Severance and Change in Control Plan and Form of Participation Agreement (Filed With SEC on July 6, 2020)

Poseida Therapeutics, Inc. Non-Employee Director Compensation Policy (Filed With SEC on July 6, 2020)

Loan and Security Agreement, by and among the Registrant, Vindico NanoBioTechnology, LLC and Oxford Finance LLC, dated July 25, 2017, as amended on May 15, 2018, August 13, 2018,... (Filed With SEC on July 6, 2020)

Agreement and Plan of Merger and Reorganization, by and among the Registrant, Hermes Merger Sub I, Inc., Hermes Merger Sub II, LLC, Vindico NanoBioTechnology, Inc. and Christopher... (Filed With SEC on June 19, 2020)

Form of Common Stock Certificate of the Registrant (Filed With SEC on June 19, 2020)

Form of Warrant issued to Oxford Finance LLC, dated July 25, 2017 (Filed With SEC on June 19, 2020)

Form of Warrant issued to Oxford Finance LLC, dated August 13, 2018 (Filed With SEC on June 19, 2020)

Form of Warrant issued to Oxford Finance LLC, dated February 11, 2019 (Filed With SEC on June 19, 2020)

Form of Indemnity Agreement, by and between the Registrant and its directors and officers (Filed With SEC on June 19, 2020)

Poseida Therapeutics, Inc. 2015 Equity Incentive Plan, as amended, and Forms of Option Grant Notice, Option Agreement and Notice of Exercise thereunder (Filed With SEC on June 19, 2020)

Executive Employment Agreement, by and between the Registrant and Eric Ostertag, dated June 1, 2015 (Filed With SEC on June 19, 2020)

Executive Employment Agreement, by and between the Registrant and Mark Gergen, dated February 19, 2018 (Filed With SEC on June 19, 2020)

Offer Letter, by and between the Registrant and Matthew Spear, dated June 13, 2016 (Filed With SEC on June 19, 2020)

Offer Letter, by and between the Registrant and Kerry Ingalls, dated July 29, 2019 (Filed With SEC on June 19, 2020)

Offer Letter, by and between the Registrant and Johanna Mylet, dated June 8, 2015 (Filed With SEC on June 19, 2020)

License Agreement, by and between the Registrant and Janssen Biotech, Inc., effective August 3, 2015 (Filed With SEC on June 19, 2020)

Commercial License Agreement, by and between the Registrant and TeneoBio, Inc., effective April 27, 2017 (Filed With SEC on June 19, 2020)

Commercial License Agreement, by and between the Registrant and TeneoBio, Inc., effective August 3, 2018 (Filed With SEC on June 19, 2020)

License Agreement, by and between the Registrant and Helmholtz-Zentrum MnchenDeutsches Forschungszentrum fr Gesundheit und Umwelt GmbH, effective May 20, 2016 (Filed With SEC on June 19, 2020)

License Agreement, by and between the Registrant and Genus Oncology, LLC, effective October 24, 2019 (Filed With SEC on June 19, 2020)

Loan and Security Agreement, by and among the Registrant, Vindico NanoBioTechnology, LLC and Oxford Finance LLC, dated July 25, 2017, as amended on May 15, 2018, August 13, 2018... (Filed With SEC on June 19, 2020)

Lease, by and between the Registrant and BMR-9360-9390 Towne Centre LP, dated October 1, 2018, as amended on October 4, 2019 and March 11, 2020 (Filed With SEC on June 19, 2020)

Lease, by and between the Registrant and BMR-Eastgate Mall LP, dated July 12, 2019 (Filed With SEC on June 19, 2020)

Form of Common Stock Certificate of the Registrant (Filed With SEC on March 4, 2019)

Form of Warrant issued to Oxford Finance LLC, dated February 11, 2019 (Filed With SEC on March 4, 2019)

Asset Contribution Agreement, by and between the Registrant and Transposagen Biopharmaceuticals, Inc., dated February 9, 2015 (Filed With SEC on January 4, 2019)

Amended and Restated Investors Rights Agreement, by and between the Registrant and certain of its stockholders, dated March 19, 2018 (Filed With SEC on January 4, 2019)

Form of Warrant issued to Oxford Finance LLC, dated July 25, 2017 (Filed With SEC on January 4, 2019)

Form of Warrant issued to Oxford Finance LLC, dated August 13, 2018 (Filed With SEC on January 4, 2019)

Form of Indemnity Agreement, by and between the Registrant and its directors and officers (Filed With SEC on January 4, 2019)

Poseida Therapeutics, Inc. 2015 Equity Incentive Plan, as amended, and Forms of Option Grant Notice, Option Agreement and Notice of Exercise thereunder (Filed With SEC on January 4, 2019)

Executive Employment Agreement, by and between the Registrant and Eric Ostertag, dated June 1, 2015 (Filed With SEC on January 4, 2019)

Executive Employment Agreement, by and between the Registrant and Mark Gergen, dated February 19, 2018 (Filed With SEC on January 4, 2019)

Offer Letter, by and between the Registrant and Matthew Spear, dated June 13, 2016 (Filed With SEC on January 4, 2019)

Offer Letter, by and between the Registrant and Johanna Mylet, dated June 8, 2015 (Filed With SEC on January 4, 2019)

License Agreement, by and between the Registrant and Janssen Biotech, Inc., effective August 3, 2015 (Filed With SEC on January 4, 2019)

Commercial License Agreement, by and between the Registrant and TeneoBio, Inc., effective April 27, 2017 (Filed With SEC on January 4, 2019)

Commercial License Agreement, by and between the Registrant and TeneoBio, Inc., effective August 3, 2018 (Filed With SEC on January 4, 2019)

License Agreement, by and between the Registrant and Helmholtz-Zentrum MnchenDeutsches Forschungszentrum fr Gesundheit und Umwelt GmbH, effective May 20, 2016 (Filed With SEC on January 4, 2019)

Poseida Therapeutics, Inc. Non-Employee Director Compensation Policy (Filed With SEC on January 4, 2019)

Agreement and Plan of Merger and Reorganization, by and among the Registrant, Hermes Merger Sub I, Inc., Hermes Merger Sub II, LLC, Vindico NanoBioTechnology, Inc. and Christopher... (Filed With SEC on January 4, 2019)

Loan and Security Agreement, by and among the Registrant, Vindico NanoBioTechnology LLC and Oxford Finance LLC, dated July 25, 2017, as amended on May 15, 2018, August 13, 2018... (Filed With SEC on January 4, 2019)

Lease, by and between the Registrant and AP3-SD1 Campus Point LLC, dated March 3, 2016, as amended on July 6, 2016 and November 4, 2016 (Filed With SEC on January 4, 2019)

Lease, by and between the Registrant and BMR-9360-9390 Towne Centre LP, dated October 1, 2018 (Filed With SEC on January 4, 2019)

Category

Industry

Companies

Contracts

Poseida Therapeutics, Inc. Contracts & Agreements